Quality of Life Is Worse at 6-10 Years after Radioactive Iodine Treatment of Graves’ Disease as Compared with Antithyroid Drugs or Surgery | oneGRAVESvoice
Global Search
Global Search

Trusted Resources: Evidence & Education

Scientific literature and patient education texts

Back to Evidence & Education / Scientific Articles

Quality of Life Is Worse at 6-10 Years after Radioactive Iodine Treatment of Graves’ Disease as Compared with Antithyroid Drugs or Surgery

key information

source: Clinical Thyroidology

year: 2019

authors: Sun Y. Lee

summary/abstract:

Background:
Graves’ disease is a common cause of hyperthyroidism and may be associated with a negative impact on patients’ quality of life (QoL). It can be accompanied by extrathyroidal complications such as ophthalmopathy, dermopathy, and acropachy. Usual treatment options include antithyroid drugs (ATDs), radioiodine (RAI), or surgery. Previous studies have reported similar general-health QoL with the three treatment methods, but were limited to shorter-term follow up. The current study was conducted to assess long-term QoL in patients with Graves’ disease who have been treated in a routine clinical setting.

Methods:
A cohort of 2916 patients with a new diagnosis of hyperthyroidism between 2003 and 2005 was established from seven centers in southern Sweden. Patients were treated according to usual clinical practice. From this cohort, 1186 patients with Graves’ disease were recruited for the current study 6 to 10 years after the original diagnosis to assess QoL measures. Those with recurrent Graves’ disease were excluded.

organization: Boston Medical Center, USA

DOI: 10.1089/ct.2019;31.144-147

read more

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Powered by

Brought to you by

Supported through an independent
educational grant by

© 2022 rareLife solutions Inc.